CASI Pharmaceuticals To Report Third Quarter 2021 Financial Results And Host Conference Call November 12, 2021

Rhea-AI Summary

CASI Pharmaceuticals, Inc. (Nasdaq: CASI) announced a conference call scheduled for November 12, 2021, at 8:00 a.m. EDT to discuss third-quarter highlights. The call, led by the Chairman & CEO, will review the company's business updates and upcoming milestones. Interested parties can join by dialing 1-877-870-4263 (U.S.) or 1-412-317-0790 (international). A replay will be available afterward. CASI focuses on developing therapeutics in China, the U.S., and globally, aiming to address unmet medical needs in hematology-oncology.

ROCKVILLE, Md. and BEIJING, Nov. 2, 2021 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announced the Company will host a conference call reviewing the third quarter highlights at 8:00 a.m. EDT on Friday, November 12^th, 2021.

On the call, CASI's Chairman & CEO will provide an update on the Company's business and upcoming milestones. The conference call can be accessed by dialing 1-877-870-4263 (U.S.) or 1-412-317-0790 (international) and ask to be joined into the CASI Pharmaceuticals call to listen to the live conference call.

This call will be recorded and available for replay by dialing 1-877-344-7529 (U.S.) or 1-412-317-0088 (international) and enter 10160251 to access the replay.

About CASI Pharmaceuticals

CASI Pharmaceuticals, Inc. is a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products in China, the United States, and throughout the world. The Company is focused on acquiring, developing and commercializing products that augment its hematology oncology therapeutic focus as well as other areas of unmet medical need. The Company intends to execute its plan to become a leader by launching medicines in the greater China market leveraging the Company's China-based regulatory and commercial competencies and its global drug development expertise. The Company's operations in China are conducted through its wholly-owned subsidiary, CASI Pharmaceuticals (China) Co., Ltd., which is located in Beijing, China. The Company has built a commercial team of more than 100 hematology-oncology sales and marketing specialists based in China. More information on CASI is available at www.casipharmaceuticals.com.

COMPANY CONTACT: CASI Pharmaceuticals, Inc. 240.864.2643 ir@casipharmaceuticals.com

INVESTOR CONTACT: Solebury Trout Bob Ai 646.378.2929 bai@soleburytrout.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/casi-pharmaceuticals-to-report-third-quarter-2021-financial-results-and-host-conference-call-november-12-2021-301413396.html

SOURCE CASI Pharmaceuticals, Inc.

FAQ

When will CASI Pharmaceuticals announce its third-quarter financial results?

CASI Pharmaceuticals will report its third-quarter financial results on November 12, 2021.

How can I listen to the CASI Pharmaceuticals conference call?

You can listen to the conference call by dialing 1-877-870-4263 (U.S.) or 1-412-317-0790 (international).

What is the focus of CASI Pharmaceuticals?

CASI Pharmaceuticals focuses on developing and commercializing innovative therapeutics for hematology-oncology and other areas of unmet medical need.

How can I access the replay of the CASI Pharmaceuticals conference call?

The replay can be accessed by dialing 1-877-344-7529 (U.S.) or 1-412-317-0088 (international) and entering access code 10160251.